A Long Term Extension Study of Ixekizumab (LY2439821) in Participants With Axial Spondyloarthritis

Inclusion Criteria:

- Have completed the final study visit in Study RHBV (NCT02696785), RHBW (NCT02696798),
or RHBX (NCT02757352).

(Note: Participants from Study RHBX are not eligible if they permanently discontinued
ixekizumab and were receiving a tumor necrosis factor [TNF] inhibitor).

- Must agree to use a reliable method of birth control.

Exclusion Criteria:

- Have significant uncontrolled disorders or abnormal laboratory values that, in the
opinion of the investigator, pose an unacceptable risk to the participant if
investigational product continues to be administered.

- Have a known hypersensitivity to ixekizumab or any component of this investigational
product.

- Had investigational product permanently discontinued during a previous ixekizumab
study.

- Had temporary investigational product interruption at any time during or at the final
study visit of a previous ixekizumab study and, in the opinion of the investigator,
restarting ixekizumab poses an unacceptable risk for the participant's participation
in the study.

- Have any other condition that, in the opinion of the investigator, renders the
participant unable to understand the nature, scope, and possible consequences of the
study or precludes the participant from following and completing the protocol.

- Are currently enrolled in any other clinical trial involving an investigational
product or any other type of medical research judged not to be scientifically or
medically compatible with this study.